Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.

Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T.

Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3.

2.

Severity of diabetic retinopathy at the first ophthalmological examination in the Lebanese population.

Harb W, Harb G, Chamoun N, Kanbar A, Harb M, Chanbour W.

Ther Adv Ophthalmol. 2018 Aug 14;10:2515841418791950. doi: 10.1177/2515841418791950. eCollection 2018 Jan-Dec.

3.

Current Procedural Terminology Codes - Why Are They Important?

Eberhardt J, Harb W.

Dis Colon Rectum. 2018 Oct;61(10):1128-1129. doi: 10.1097/DCR.0000000000001190. No abstract available.

PMID:
30113340
4.

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA.

Clin Cancer Res. 2018 May 29. doi: 10.1158/1078-0432.CCR-18-0494. [Epub ahead of print]

PMID:
29844129
5.

Corneal Stroma Enhancement With Decellularized Stromal Laminas With or Without Stem Cell Recellularization for Advanced Keratoconus.

Alió Del Barrio JL, El Zarif M, Azaar A, Makdissy N, Khalil C, Harb W, El Achkar I, Jawad ZA, de Miguel MP, Alió JL.

Am J Ophthalmol. 2018 Feb;186:47-58. doi: 10.1016/j.ajo.2017.10.026. Epub 2017 Dec 13.

PMID:
29103962
6.

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).

Boccia RV, Bessudo A, Agajanian R, Conkling P, Harb W, Yang H, Pinchasik D, Kimball AS, Berenson JR.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):433-437. doi: 10.1016/j.clml.2017.05.009. Epub 2017 May 10.

7.

Cellular Therapy With Human Autologous Adipose-Derived Adult Stem Cells for Advanced Keratoconus.

Alió Del Barrio JL, El Zarif M, de Miguel MP, Azaar A, Makdissy N, Harb W, El Achkar I, Arnalich-Montiel F, Alió JL.

Cornea. 2017 Aug;36(8):952-960. doi: 10.1097/ICO.0000000000001228.

PMID:
28486314
8.

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R.

Am J Hematol. 2017 May;92(5):460-466. doi: 10.1002/ajh.24687. Epub 2017 Mar 22.

9.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG.

Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12.

10.

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ.

Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. Epub 2016 May 5. No abstract available.

11.

Crohn's Disease of the Colon, Rectum, and Anus.

Harb WJ.

Surg Clin North Am. 2015 Dec;95(6):1195-210, vi. doi: 10.1016/j.suc.2015.07.005. Epub 2015 Oct 21. Review.

PMID:
26596922
12.

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.

Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL.

Clin Cancer Res. 2016 Mar 1;22(5):1059-66. doi: 10.1158/1078-0432.CCR-15-0624. Epub 2015 Oct 19.

13.

Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options.

Harb WA.

Cancer Manag Res. 2015 Jan 21;7:37-46. doi: 10.2147/CMAR.S72592. eCollection 2015. Review.

14.

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB.

J Clin Oncol. 2014 Nov 10;32(32):3626-33. doi: 10.1200/JCO.2014.56.3809. Epub 2014 Oct 6.

PMID:
25287822
15.

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

Morris RT, Joyrich RN, Naumann RW, Shah NP, Maurer AH, Strauss HW, Uszler JM, Symanowski JT, Ellis PR, Harb WA.

Ann Oncol. 2014 Apr;25(4):852-8. doi: 10.1093/annonc/mdu024.

PMID:
24667717
16.

Thiopurine methyltransferase genotyping in Palestinian childhood acute lymphoblastic leukemia patients.

Ayesh BM, Harb WM, Abed AA.

BMC Hematol. 2013 Apr 10;13(1):3. doi: 10.1186/2052-1839-13-3.

17.

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS.

Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25. Erratum in: Adv Ther. 2014 Sep;31(9):1008-9.

18.

Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay.

Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, Ionescu-Zanetti C.

Transl Oncol. 2013 Oct 1;6(5):528-38. eCollection 2013.

19.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, Ghazal HH, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, Vescio R.

Ann Hematol. 2014 Jan;93(1):89-98. doi: 10.1007/s00277-013-1910-2. Epub 2013 Oct 18.

PMID:
24135804
20.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.

J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.

PMID:
24127448
21.

Reluctance to screening colonoscopy in Arab Americans: a community based observational study.

Talaat N, Harb W.

J Community Health. 2013 Aug;38(4):619-25. doi: 10.1007/s10900-013-9688-7.

PMID:
23564366
22.

Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.

Riggs H, Jalal SI, Baghdadi TA, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W, Hanna N.

Clin Lung Cancer. 2013 May;14(3):224-9. doi: 10.1016/j.cllc.2012.09.004. Epub 2012 Oct 24.

PMID:
23102811
23.

Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.

Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB.

J Thorac Oncol. 2012 Oct;7(10):1618-21.

24.

Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.

Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J, Hanna N.

J Thorac Oncol. 2010 Nov;5(11):1815-20. doi: 10.1097/JTO.0b013e3181ee820c.

25.

Differentiated thyroid cancer associated with intestinal polyposis syndromes: a review.

Harb WJ, Sturgis EM.

Head Neck. 2009 Nov;31(11):1511-9. doi: 10.1002/hed.21156. Review.

PMID:
19536760
27.

Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension.

Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM.

Head Neck. 2007 Aug;29(8):731-40.

PMID:
17274049
28.

Effect of cucurbitacins on bilirubin-albumin binding in human plasma.

Greige-Gerges H, Abou Khalil R, Chahine R, Haddad C, Harb W, Ouaini N.

Life Sci. 2007 Jan 16;80(6):579-85. Epub 2006 Oct 14.

PMID:
17097690
29.

A case of foot drop as an expression of brain metastases?

Djekidel M, Harb W.

Neurologist. 2006 Sep;12(5):274-5.

PMID:
16990742
30.

Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.

Mundy DW, Harb W, Jevremovic T.

Phys Med Biol. 2006 Mar 21;51(6):1377-91. Epub 2006 Feb 21.

PMID:
16510950
31.

The cancer cachexia syndrome: a review of metabolic and clinical manifestations.

Esper DH, Harb WA.

Nutr Clin Pract. 2005 Aug;20(4):369-76. Review.

PMID:
16207677
32.

A model for double asymmetric induction in the stereocontrolled reduction of glycosyl alpha-ketoesters with oxazaborolidines.

Harb W, Ruiz-López MF, Coutrot F, Grison C, Coutrot P.

J Am Chem Soc. 2004 Jun 9;126(22):6996-7008.

PMID:
15174869
33.

Nodular melanoma of the face: a rare finding in African Americans.

Beech DJ, Harb W, Reed J.

Am Surg. 2004 Apr;70(4):294-7.

PMID:
15098778
34.

Quantification of phthalocyanine concentration in rat tissue using laser-induced fluorescence spectroscopy.

Panjehpour M, Sneed RE, Frazier DL, Barnhill MA, O'Brien SF, Harb W, Overholt BF.

Lasers Surg Med. 1993;13(1):23-30.

PMID:
8426523
35.

Experimental allergic encephalomyelitis in mice: presence of myelin basic protein in cerebrospinal fluid.

Rauch HC, Montgomery IN, Hinman CL, Harb W.

J Neuroimmunol. 1987 May;15(1):73-83.

PMID:
2437153
36.

Chronic Theiler's virus infection in mice: appearance of myelin basic protein in the cerebrospinal fluid and serum antibody directed against MBP.

Rauch HC, Montgomery IN, Hinman CL, Harb W, Benjamins JA.

J Neuroimmunol. 1987 Feb;14(1):35-48.

PMID:
2433306

Supplemental Content

Support Center